Home / News / Scientific Beta plots how deglobalisation hits stocks

Scientific Beta plots how deglobalisation hits stocks

War and plague have disrupted the geopolitical peace over the last three years with far-reaching consequences for international trade and economic growth.
News

If COVID exposed the flaws of “just-in-time” supply chains, the outbreak of conflict in Ukraine and growing tensions elsewhere (notably between China and the US, and Gaza) put the globalisation trend on ice.Offshoring has been replaced by “reshoring” or “friendshoring” in world power-broker jargon as US Treasury Secretary, Janet Yellen, noted in a 2022 speech.

“Rather than being highly reliant on countries where we have geopolitical tensions and can’t count on ongoing, reliable supplies, we need to really diversify our group of suppliers,” Yellen said.

The changing ‘deglobalisation’ trade dynamic also requires investors to better-understand any ensuing risks or opportunities for their portfolio companies, factor index specialist, Scientific Beta, argues in a new paper.“

  • Shifts in trade policy influence the structure of the economy, creating winners and losers,” the Scientific Beta study says.

    “Trade policy clearly influences the financial performance of firms. Moreover, shifts in trade policy will have heterogeneous effects across such businesses; some may benefit from a more globalised market via reduced input costs or more export opportunities, while others may benefit from the introduction of protectionist policies via a reduction in foreign competition.”

    The analysis found a “statistically and economically significant” difference of 1.4 per cent weekly price change in the shares of companies with high and low exposures to trade policy changes (such as tariff increases). Erik Christiansen, Scientific Beta head of investment solutions, said the new company-level trade exposure offers “another risk management” metric for portfolio investors.

    In NZ last week, Christiansen said the trade-related overlay could help investors reduce exposure to “unrewarded risks”, a core part of the Scientific Beta process.

    “Among others, we expect the measure to be useful for investors who want to manage the trade policy risk exposure in their equity portfolio, or for researchers interested in the economic effects of international trade policy or asset pricing,” the Scientific Beta study says.

    The index firm, majority owned by the Singapore Stock Exchange, offers a range of factor-based indices as well as ESG (especially climate-related) benchmarks with various risk-tuning options.

    “We focus on diversification,” he said, which has seen the Scientific Beta benchmarks underperform the US cap-weighted indices over the last few years where a handful of stocks have dominated returns.

    But while the Magnificent Seven may have distorted the US index – for now at least – Christiansen said less-concentrated emerging markets have proven more fertile ground for highly diversified multi-factor strategies. Diversification, he said, is primarily for risk management rather than to juice returns.

    Founded in France in 2012 as part of the academic, EDHEC-Risk Institute, Scientific Beta has about US$60 billion in ‘assets under replication’. The group opened an office in Australia in 2022 with Susan Rodgers as business development director and senior investment specialist, Mike Aked. Last month Aked left to take up the role of senior investment manager in the Australian wealth management division of Credit Suisse (now part of UBS).

    This article originally appeared on InvestmentNews NZ.

    David Chaplin

    David Chaplin is a reputed financial services journalist and publisher of Investment News NZ.




    Print Article

    Related
    What poor investment governance really costs members

    A new report “from the coalface” of super fund investing has gone some way to quantifying the cost of shonky investment management, with members potentially losing out on hundreds of thousands of dollars.

    Lachlan Maddock | 2nd May 2024 | More
    ‘It comes at a cost’: Small funds fret APRA levy increase

    A number of super funds managing less than $10 billion have been slugged with an increase in their restricted APRA levy of more than 80 per cent even as the regulator pushes them to keep costs down.

    Lachlan Maddock | 30th Apr 2024 | More
    Megafunds split on future of YFYS

    Australia’s biggest super funds disagree on what the new Your Future, Your Super performance test should look like, but they both think the consequences for failure should be just as weighty – and apply to everybody equally.

    Lachlan Maddock | 26th Apr 2024 | More
    Popular